Breaking Free from Corticosteroids in Crohn's Disease.

This editorial discusses the post-hoc analysis by Dubinsky et al. evaluating upadacitinib's efficacy and safety by baseline corticosteroid use in Crohn's disease, highlighting its corticosteroid-sparing potential, the need for standardized tapering in trials, and the implications for achieving durable corticosteroid-free remission.